Manufacturing Issues Result in FDA Rejection of Atara’s Cell Therapy

Atara Therapeutics’ Ebvallo, already marketed in Europe for a transplant-related blood cancer, will not hit the U.S. market just yet, forcing the company to “significantly reduce expenses.”